Stockreport

UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF 18-month duration of response (DOR) data from ENVISION, and integrated patient-reported outcomes (PROs) from UGN-102-treated patients in OPTIMA II, ATLAS and ENVISION in [Read more]